The Center for Immunoengineering at Georgia Tech has awarded the inaugural Singh Family Research Awards to two faculty members and two students advancing innovative immunoengineering projects.

A Georgia Tech-led research team has received up to $6 million to develop SHIELD, a new platform designed to rapidly create immune-based countermeasures against a wide range of deadly biological threats.

A team of researchers led by Ankur Singh has been awarded up to $6 million from DTRA of the U.S. Department of Defense to accelerate the development of MCMs against deadly biological threats that endanger public health, national security, and warfighters.

Research published in Science Advances demonstrated the effectiveness of this technology in protecting high-value engineered cell lines.

Georgia Tech engineers have created electronics-free robotic swarms whose collective intelligence emerges entirely from mechanical design, enabling coordinated behavior for applications in medicine, space, and beyond.

Georgia Tech has named the 2026 Institute Research Award recipients, recognizing faculty, staff, and research teams whose work advances innovation, mentorship, collaboration, and societal impact across the Institute’s research enterprise.

Researchers have visualized mosquito flight behavior for the first time — which could improve mosquito-control strategies.

When Mason Chilmonczyk, M.S. ME 2017, Ph.D. ME 2020, arrived at Georgia Tech to pursue graduate degrees in mechanical engineering, his goal was to become a professor. Instead, an unexpected turn in his research led him to entrepreneurship.

Georgia Tech researchers have developed a breakthrough system to manufacture valuable amino acids. It’s the most efficient system of its kind — and removes more carbon from the atmosphere than it emits.

The Sandia partnership will expand research impact, talent pipelines, and national security innovation.

To address this issue, researchers at Georgia Tech have developed a new, flexible, sensor-filled fabric to monitor areas at risk of PIs and alert hospital staff when a patient needs to be turned.

Housley and his team are developing self‑assembling nanohydrogels that deliver cancer drugs only when they reach tumor‑specific conditions, aiming to reduce side effects and make treatment more precise across multiple cancer types.